Pharmaceutical manufacturing: campaign scheduling under a release process nobody can rush

Campaigns, cleaning and the capacity nobody counts

Equipment trains are shared between products, so a plant runs one product for a stretch, then cleans, verifies the cleaning, and reconfigures. Cleaning validation defines how much effort that transition requires, and for potent or highly coloured products the requirement can be severe. The scheduling consequence is that campaign length is an economic decision: long campaigns amortise changeover but build inventory and reduce responsiveness. Sites that report low equipment utilisation while refusing new work are usually telling the truth, because the constraint is the number of changeovers the site can validate and execute rather than the hours the machines could theoretically run.

A batch is not product until the record clears review

Manufacture ends; the batch then waits for analytical results and for review of the executed record, and any deviation encountered during production must be investigated and closed before a qualified person can release. A single unexplained event, a fill weight excursion or an environmental monitoring result, can hold a batch for weeks while the investigation establishes whether product quality was affected. Deviations therefore behave like production stoppages that occur after production. Sites that keep deviation numbers low do so by designing processes with margin, not by recording less, and their inventory cover is correspondingly smaller.

Change control is a commercial constraint wearing a quality costume

Switching an excipient supplier, moving a process to a different machine, or adding a manufacturing site are regulatory events, assessed and often filed with authorities before implementation. Different markets evaluate the same change on different timetables, so a global product can end up with parallel supply arrangements while approvals catch up. This is why pharmaceutical supply chains look inflexible: the alternative supplier may be technically fine and commercially attractive, yet unusable for a year. Procurement in this sector negotiates continuity and change notification more aggressively than price, because a surprise from a supplier is a regulatory problem, not a sourcing one.

Validation and tech transfer are the entry ticket

Before commercial supply, the process must be shown to perform consistently at scale, supported by engineering runs, performance qualification batches and a stability programme that runs for as long as the intended shelf life requires. Transferring a product between sites repeats much of this. The cost is not only money but calendar, and it is incurred before any revenue exists. Companies planning a second source frequently underestimate the analytical method transfer element, where the receiving laboratory must demonstrate it obtains equivalent results, and where small differences in equipment or reagents produce months of troubleshooting.

Where the cost actually sits on a drug site

For most solid dose products the active ingredient is not the dominant cost of the finished item. The dominant costs are people, particularly the quality and analytical organisation, plus clean utilities, facility overhead and capacity lost to cleaning and changeover. That has a strategic consequence: cost reduction programmes aimed at material prices achieve little, while reducing product complexity, extending campaign lengths and cutting deviation rates achieve a lot. It also explains why sites with many low-volume products struggle, since quality workload scales with the number of distinct products and markets rather than with output.

Frequently asked questions

Why does a site with idle equipment say it cannot take another product?

Because capacity in this sector is measured in validated changeovers and quality workload, not machine hours. Every additional product brings cleaning validation, stability commitments, analytical method maintenance, regulatory filings per market and its own share of deviations and investigations. A site can have vessels standing still and still be unable to absorb another product without expanding the quality organisation, which is slower and more expensive than adding equipment.

What does it take to qualify a second manufacturing site for an existing product?

Technology transfer of the process and of the analytical methods, demonstration batches at the receiving site, comparative data showing the product is equivalent, stability studies on material made there, and regulatory submissions in every market where the product is sold. Approval timelines differ by market, so a company often runs both sites in parallel for an extended period. The analytical transfer is usually the step that overruns, not the manufacturing itself.

Why is a single deviation treated so seriously?

Because it represents a departure from the process that was approved and validated, and until the investigation establishes otherwise, the affected batch cannot be assumed to meet its specification. The investigation must identify what happened, assess product impact, and determine whether other batches are implicated. Beyond the specific batch, patterns of repeated deviations attract inspector attention, and unresolved or superficially closed investigations are among the findings most likely to escalate during an inspection.